Median Technologies’ Post

💫 Pleased and very proud to announce today that eyonis™ LCS, our proprietary AI/ML-powered Software as Medical Device for lung cancer screening met the primary and all secondary endpoints in REALITY, the first of two pivotal studies required for marketing authorizations in U.S. and Europe! 🎤 "These data met our ambition for improving the performance of LDCT with eyonis™ LCS. Now, we are even more excited to report the upcoming RELIVE pivotal data and file for marketing authorizations in H1 2025. We believe that broad implementation of LDCT with eyonis™ LCS has the potential to vastly improve early detection and lead to far more cures, dramatically reducing lung cancer mortality.” said Fredrik Brag, CEO of Median. 🎤 “The high performances of our device can not only save lives but also prevent healthy patients undergoing unnecessary medical procedures. This will avoid unnecessary distress for patients and reduce healthcare costs”, added Thomas Bonnefont, COO & CCO of Median eyonis BU. 👏 Huge kudos to Median and eyonis teams, for this fantastic work! 👏 Want to read the full story? -> https://lnkd.in/etuq85zr

Only one day left until the #ESMO24 Congress kicks off! Are you ready to experience the future of medical imaging and clinical trials? Join our #eyonis™ and #iCRO teams at booth #525 from Sept 13th to 17th. Swing by to explore our cutting-edge AI/ML tech-based suite of software as medical devices (#SaMD) and learn about #clinicaltrial imaging solutions. Don't miss this opportunity to connect with us. Secure your spot to meet us: https://lnkd.in/d3RHtqSq See you tomorrow! Let's innovate together!

We’re thrilled to introduce our latest AI-powered services, designed to help biopharmaceutical companies accelerate the development of cancer drugs. Join Sébastien Jacques, Head of Imaging Lab, at #ESMO24 to explore how our cutting-edge technologies can elevate your #oncologytrials:   🔍 Enhancing Patient Stratification and Outcomes: With AI, we standardize drug efficacy results from early phases, ensuring accurate insights to guide your next steps.   📊 Delivering Predictive Patient Insights: We harness Median’s proprietary AI system to build advanced models that identify responders and non-responders, optimizing treatment strategies in oncology trials.   🧩 Boosting Confidence in Reads: We use AI for lesion identification in central reads monitoring, reducing discrepancies and boosting confidence in your data.   Discover how these services can drive success in your trials. Book a meeting with our Head of Imaging Lab here: https://lnkd.in/dBz_9QNT   #DrugDevelopment #ClinicalTrials #Innovation #HealthcareAI

⏰ Rendez vous ce soir 17h00 pour un webinar #BiotechFinances sur le cancer du poumon, avec, autour de Jacques-Bernard Taste, Fredrik Brag, CEO de Median Technologies, Nicolas Poirier, OSE Immunotherapeutics et ERic Halioua, PDC*line Pharma. 📍 Le cancer du poumon est la première cause de mortalité par cancer au monde (données OMS 2022) et, lors de ce webinar, il sera question des dernières avancées thérapeutiques et diagnostiques pour améliorer les taux de survie de ce cancer à pronostic défavorable, dont la mortalité est majoritairement liée à un diagnostic trop tardif. 📍Fredrik Brag partagera son point de vue sur le rôle majeur que peuvent jouer les technologies de l’IA appliquées à l’imagerie dans le dépistage du cancer du poumon, avec un focus sur le logiciel dispositif médical eyonis LCS de Median, en cours d’étude pivot. 📍Dans un contexte où le dépistage du cancer du poumon existe déjà aux États Unis, et où ces pratiques de dépistage se mettent rapidement en place dans les pays européens, de nouveaux espoirs émergent pour les patients atteints de ce cancer, grâce à l’innovation en santé …

✨ Catch Us at #ESMO24! ✨   Median’s clinical trial imaging team is excited to be part of ESMO 2024!   👋 Visit us at Booth #525 to meet our imaging experts and discover how we can elevate your oncology programs. From central imaging services to AI/ML-powered insights, we’re here to tailor innovative solutions that meet your specific trial needs and accelerate success.   Swipe through to meet the team who will be there, eager to discuss how we can help accelerate your clinical trial success. We look forward to seeing you at ESMO 2024! 🔗 Book a meeting here: https://lnkd.in/dBz_9QNT   #ESMO24 #Oncology #ClinicalTrials #ImagingSolutions #Drugdevelopment #AIinHealthcare #Innovation #LifeSciences

🌟 Vous avez manqué notre webconférence en direct hier ? Pas de souci ! 🌟 Fredrik Brag, CEO et Fondateur de Median Technologies, a fait un point sur eyonis™ LCS, notre logiciel dispositif médical pour le diagnostic précoce du cancer du poumon. Le replay de la webconférence est maintenant disponible ! Ne manquez pas cette occasion de vous tenir informé des dernières nouvelles et mises à jour de Median Technologies. 👉 Regardez le replay ici : https://lnkd.in/dRVjgKzg

🌟 Missed our live webcast yesterday? We've got you covered! 🌟 Fredrik Brag, CEO and Founder of #MedianTechnologies delivered an insightful update about eyonis™ LCS, Median’s proprietary next generation AI/ML tech-based Software as Medical Device (SaMD) to help diagnose lung cancer patients at early stage. The replay is now available, so don't miss the chance to stay informed! 👉 Watch the recording here: https://lnkd.in/diRRWWWs

From Sept 13th to 17th, our #eyonis™ team will be pleased to welcome you at booth #525 in Barcelona for #ESMO2024 and present the latest updates of #eyonis™, our suite of end-to-end AI/ML tech-based CADe/CADx Software as Medical Device (#SaMD) for early cancer diagnosis. Want to know more about eyonis™ ? Click here: https://lnkd.in/dBz_9QNT Hope to see you there! #medicalimaging #clinicaltrials #Aitechforhealth

✨ We will be sharing information on eyonis™ LCS, including recently announced data from the pivotal REALITY study, at Booth #2601 during the 2024 World Conference on Lung Cancer, being held in San Diego, CA, USA, from September 7-10, 2024. 📌 With eyonis™ LCS, we, at Median are working to provide the U.S. and European lung cancer medical communities with a unique breakthrough software as medical device to help medical professionals expedite lung cancer screening programs! 🌍 The WCLC, the premier world conference on lung cancer, is organized by the International Association for the Study of Lung Cancer (IASLC), a global multidisciplinary association dedicated to eradication of all forms of lung cancers. 💡 Want to know more? https://lnkd.in/gXs7fNqM #eyonis #AIforbetterhealth #patientfirst #mediantechnologies